Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration University of Antwerp
As the mitogen-activated protein kinase (MAPK) signalling pathway is activated in many paediatric cancers, it is an important therapeutic target. Currently, a range of targeted MAPK pathway inhibitors are being developed in adults. However, MAPK signals through many cascades and feedback loops and perturbing the MAPK pathway may have substantial influence on other pathways as well as normal development. In view of these issues, the ninth ...